Siksika Health Services, Orpyx, and GMAK Consulting Collaborate to Help Eliminate Foot Complications for Patients with Type 2 Diabetes through the PATHWAYS Indigenous Health Collaborations Program – Yahoo Finance

CALGARY, AB, Oct. 20, 2022 /CNW/ — Siksika Health Services (SHS) has partnered with Orpyx^® Medical Technologies (Orpyx) on a pilot program to help prevent and reduce the occurrence and recurrence of diabetic foot ulcers (DFU) for Siksika members with Type 2 Diabetes (T2D). Funding is through PATHWAYS Indigenous Health Collaborations, a partnership with Boehringer Ingelheim (Canada) Ltd., and Bimaadzwin, with the support of GMAK Consulting. This 24-week pilot will assess the effectiveness of using a digital therapeutic solution, Orpyx SI^® Flex Sensory Insoles with Remote Patient Monitoring (RPM) services, to prevent DFUs. The pilot will be available to 35 Siksika Nation members currently living with Type 2 Diabetes.
“Partnerships and access to technology like this allow Siksika Health Services to assist our Nation members who live with diabetes like never before,” commented Dr. Tyler White, CEO of Siksika Health Services. “It’s about quality of life and health improvement, which is ultimately what we are after here. So, I’m proud to collaborate with medical innovators like Orpyx and GMAK Consulting.”
Approximately 25% of people living with diabetes will develop a DFU in their lifetime¹, with 49% DFU recurrence in the first year and 68% recurrence within five years². In Alberta, there is one amputation every 22 hours resulting from a DFU.³ Diabetes is a particularly devastating disease for Indigenous populations in Canada, with 17.2% of on-reserve Indigenous populations diagnosed with diabetes compared to 10% of non-Indigenous populations.⁴
“This collaboration is the first step in eliminating preventable DFUs within the Indigenous populations”, stated Dr. Breanne Everett, CEO and President of Orpyx. “Our long-term goal is to support Siksika Health Services in building a sustainable and cost-effective remote patient monitoring pathway for the delivery of quality health care to the Siksika Nation community.”
“What is exciting about this multi-collaboration with Siksika First Health Services and Orpyx is their innovative approach to the prevention of foot ulcers due to complications of T2D with the use of Orpyx SI^® Flex Sensory Insoles and remote patient monitoring for their community members,” elaborated Allison Deer, Bimaadzwin Senior Project Advisor. “Far too many of our people have lost limbs to this chronic disease and we are excited to contribute to a project that embraces amputation prevention. Our purpose at PATHWAYS is to optimize patient care and improve health outcomes through collaboration with the private and public sectors of development with the community as the driver of system change. We are proud to support this community-driven pilot to test grassroots solutions with potential national impact and begin to close the healthcare gaps for our people across Turtle Island.”
About the Partners
Siksika Health Services (SHS) is a leader in providing quality, holistic health care to its members, and restoring a state of wellness through accountable and efficient service delivery as recognized by Accreditation Canada since 2005. With a population of more than 8,000 people, Siksika Nation located one hour east of Calgary, is considered one of Canada’s most technologically advanced and progressive First Nation communities, including being a leading community primary service provider.
Orpyx Medical Technologies (Orpyx) is a digital therapeutic company with a comprehensive turnkey solution to extend the health span for people living with diabetes. Supported by a robust intellectual property portfolio of >90 patents, the Orpyx SI^® Sensory Insole system, with remote patient monitoring, has been clinically proven to help detect and prevent complications caused by diabetic peripheral neuropathy. The insoles contain embedded sensors that have extensive capabilities to measure real-world physiological and physical parameters, which are then available to patients and their providers resulting in continuity of personalized and preventative care.
Bimaadzwin means ‘life’ or ‘good path’ in Anishinaabe. An Indigenous-led consulting and policy group whose focus is on enabling First Nations communities to successfully reconstitute Nationhood by advancing health governance and economic development.
Boehringer Ingelheim (Canada) Ltd. is a global, research-driven pharmaceutical company embracing many cultures and diverse societies.
GMAK Consulting has supported transformative healthcare and partnerships for diverse populations, including Indigenous health, for over 20 years as a clinician, senior leader, strategist, and innovator. GMAK Consulting facilitated introductions between SHS and Orpyx and will be involved in the project from a clinical, cultural, and healthcare perspective.
Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005; 366(9498): 1725-35
David G. Armstrong, D.P.M., M.D., Ph.D., Andrew J.M. Boulton, M.D., and Sicco A. Bus, Ph.D., Diabetic Foot Ulcers and Their Recurrence. N Engl J Med 2017; 376:2367-2375
https://www.woundscanada.ca/leader-change-maker/awareness-campaigns/foot-health-awareness-month
https://www.diabetes.ca/resources/tools—resources/indigenous-communities-and-diabetes
SOURCE Orpyx Medical Technologies Inc.
View original content: http://www.newswire.ca/en/releases/archive/October2022/20/c8331.html
The Gaithersburg vaccine maker has earned the Centers for Disease Control and Prevention’s recommendation to make its protein-based shot available as a booster to adults in the U.S., the last hurdle required before people can use it beyond a primary series. The CDC said late Wednesday that its director, Dr. Rochelle Walensky, greenlit the decision — which gives initially vaccinated adults the choice to get Novavax’s jab as a booster instead of the updated Omicron-specific shots from Pfizer-BioNTech or Moderna. Novavax’s vaccine instead uses a decades-old technology found in vaccines for viruses such as flu and whooping cough, which the company is hoping will spur demand from people unable to, or who choose not to, receive the newer mRNA vaccines.
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval.
Shares of Talaris Therapeutics Inc. tumbled 21.5% in premarket trading on Thursday after the company reported one of the participants in its Phase 3 study of living donor kidney transplant recipients died. The patient had been diagnosed with a moderate form of acute graft-vs-host disease. The trial's oversight committee has said enrollment and dosing may continue, and it said changes in the study's protocol to mitigate the risk of aGvHD are "sufficient." Talaris shares have declined 84.7% this y
We’re in a volatile bear market right now, and key riddle investors need to answer is, which stocks are going to bring the best returns, even in today’s uncertain conditions. One market segment that can’t be ignored is the low-cost penny stocks. These equities, typically priced under $5 per share, offer the best combination of risk and reward: a minimal cost of entry, and frequently triple-digit upside potential. Going beyond the argument that you get more for your money, even minor price apprec
If the Centers for Disease Control and Prevention follows the recommendations, the shots will be part of lists that include measles, tetanus and other inoculations recommended for adults and children.
The WHO found that omicron subvariant XBB, which may be even more resistant to antibodies than other variants, spread to more countries in the week ending Oct. 16 from the previous week.
Food and Drug Administration (FDA) authorization for a product typically delivers a nice stock price boost for the affected company. This, however, wasn't the case with vaccine specialist Novavax (NASDAQ: NVAX) on Hump Day, as the latest FDA green light had the opposite effect, driving the shares down by almost 4% on the day. The FDA has granted emergency use authorization (EUA) for Novavax's booster coronavirus shot, an adjuvanted version of its NVX-CoV2373.
Improving COVID booster numbers won’t be easy, according to Pfizer CEO Albert Bourla.
With that said, let's examine two biotech stocks that could be excellent long-term bets: CRISPR Therapeutics (NASDAQ: CRSP) and Sarepta Therapeutics (NASDAQ: SRPT). CRISPR Therapeutics is a clinical-stage biotech. The company's targets include several forms of cancer and two rare blood-related conditions called sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT).
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.
With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations. With fewer shots needed, vaccine makers including Pfizer Inc, partner BioNTech SE, rival Moderna Inc and Novavax Inc could have to hike prices as much as three times current levels if they hope to meet Wall Street revenue forecasts for the shots for 2023 and beyond, several analysts said. Last year, many on Wall Street were estimating the number of COVID-19 shots would be in line with the annual flu vaccine, which is the vaccine market leader with more than 160 million shots per year in the United States and 600 million shots globally.
Shares of Biogen (NASDAQ: BIIB) have been volatile in the past few years, largely hinging on success of the company's Alzheimer's treatments. Sales in recent years have been declining, and the loss of patent protection for top-selling multiple sclerosis treatment Tecfidera is only exacerbating those concerns. What will the company's business look like over the next five years, and is it promising enough for investors to buy shares of Biogen today?
A nursing home in Homestead recently traded for $18.63 million, according to public records. Signature Healthcare of Brookwood Gardens at 1990 S. Canal Dr. was acquired by 1990 South Canal Dr LLC on Oct.
Milestone (MIST) reports positive top-line results from its late-stage study evaluating its lead candidate, etripamil, in patients with paroxysmal supraventricular tachycardia. The results fail to impress investors.
Cathie Wood's ARK Innovation ETF (NYSEMKT: ARKK) invests in companies that have massive potential to benefit from breakthroughs in disruptive innovation, specifically in fields like genomic sequencing, gene editing, and artificial intelligence. Teladoc Health's (NYSE: TDOC) claim to fame is its flagship telehealth service, which uses its digital platform to connect subscribers to healthcare professionals like doctors via a phone call or video call. While it's true that telehealth isn't a solution that's applicable to every health issue someone might have, the convenience of having a doctor one phone call away is tough to beat.
Increasing expenses amid inflation is shrinking margins for the Zacks Medical-Hospital industry players. However, HCA Healthcare (HCA), Acadia Healthcare (ACHC), Universal Health (UHS) and Tenet Healthcare (THC) are poised to win big with recovering patient volumes.
Here’s a comprehensive checklist for your Medicare coverage—take the time to review what you have, and what you’ll need next year
Cases of “troublesome” COVID-19 variants BQ.1 and BQ.1.1 are quickly rising in the U.S. Here’s what you need to know.
These drugmakers have bucked the overall market's downward trend this year and expectations are still high.

source